Show simple item record

dc.contributor.authorHalvorsen, Tarje Onsøien
dc.contributor.authorSundstrøm, Stein Harald
dc.contributor.authorFløtten, Øystein
dc.contributor.authorBrustugun, Odd Terje
dc.contributor.authorBrunsvig, Paal Fr.
dc.contributor.authorAasebø, Ulf
dc.contributor.authorBremnes, Roy M.
dc.contributor.authorKaasa, Stein
dc.contributor.authorGrønberg, Bjørn Henning
dc.date.accessioned2018-03-27T10:57:27Z
dc.date.available2018-03-27T10:57:27Z
dc.date.issued2016-08-23
dc.description.abstract<b>Background:</b> Many patients with limited disease small cell lung cancer (LD SCLC) suffer from comorbidity. Not all patients with comorbidity are offered standard treatment, though there is little evidence for such a policy. The aim of this study was to investigate whether patients with comorbidity had inferior outcomes in a LD SCLC cohort. <br><b>Material and methods:</b> We analyzed patients from a randomized study comparing two three-week schedules of thoracic radiotherapy (TRT) plus standard chemotherapy in LD SCLC. Patients were to receive four courses of cisplatin/etoposide and TRT of 45 Gy/30 fractions (twice daily) or 42 Gy/15 fractions (once daily). Responders received prophylactic cranial irradiation (PCI). Comorbidity was assessed using the Charlson Comorbidity Index (CCI), which rates conditions with increased one-year mortality. <br><b>Results:</b> In total 157 patients were enrolled between May 2005 and January 2011. Median age was 63 years, 52% were men, 16% had performance status 2, and 72% stage III disease. Forty percent had no comorbidity; 34% had CCI-score 1; 15% CCI 2; and 11% CCI 3–5. There were no significant differences in completion rates of chemotherapy, TRT or PCI across CCI-scores; or any significant differences in the frequency of grade 3–5 toxicity (p ¼ 0.49), treatment-related deaths (p ¼ 0.36), response rates (p ¼ 0.20), progression-free survival (p ¼ 0.18) or overall survival (p ¼ 0.09) between the CCI categories. <br><b>Conclusion:</b> Patients with comorbidity completed and tolerated chemo-radiotherapy as well as other patients. There were no significant differences in response rates, progression-free survival or overall survival – suggesting that comorbidity alone is not a reason to withhold standard therapy in LD SCLC.en_US
dc.identifier.citationHalvorsen, T.O., Sundstrøm, S.H., Fløtten, Ø., Brustugun, O.T., Brunsvig, P.F., Aasebø, U., ... Grønberg, B.H. (2016). Comorbidity and outcomes of concurrent chemo- and radiotherapy in limited disease small cell lung cancer. Acta Oncologica, 55(11):1349-1354en_US
dc.identifier.cristinIDFRIDAID 1401776
dc.identifier.doi10.1080/0284186X.2016.1201216
dc.identifier.issn0284-186X
dc.identifier.issn1651-226X
dc.identifier.urihttps://hdl.handle.net/10037/12451
dc.language.isoengen_US
dc.publisherTaylor & Francis
dc.relation.journalActa Oncologica
dc.rights.accessRightsopenAccessen_US
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762en_US
dc.subjectVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Oncology: 762en_US
dc.titleComorbidity and outcomes of concurrent chemo- and radiotherapy in limited disease small cell lung canceren_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record